WO2007116278A3 - Antiangiogenic peptide and therapeutic uses thereof - Google Patents

Antiangiogenic peptide and therapeutic uses thereof Download PDF

Info

Publication number
WO2007116278A3
WO2007116278A3 PCT/IB2007/000831 IB2007000831W WO2007116278A3 WO 2007116278 A3 WO2007116278 A3 WO 2007116278A3 IB 2007000831 W IB2007000831 W IB 2007000831W WO 2007116278 A3 WO2007116278 A3 WO 2007116278A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic uses
antiangiogenic peptide
antiangiogenic
peptide
antichemotactic
Prior art date
Application number
PCT/IB2007/000831
Other languages
French (fr)
Other versions
WO2007116278A2 (en
Inventor
Claudio Brigati
Eva Raffaella Dell
Erika Nieddu
Roberto Benelli
Douglas M Noonan
Adriana Albini
Original Assignee
Istituto Naz Per La Ricerca Su
Claudio Brigati
Eva Raffaella Dell
Erika Nieddu
Roberto Benelli
Douglas M Noonan
Adriana Albini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Naz Per La Ricerca Su, Claudio Brigati, Eva Raffaella Dell, Erika Nieddu, Roberto Benelli, Douglas M Noonan, Adriana Albini filed Critical Istituto Naz Per La Ricerca Su
Priority to JP2009502246A priority Critical patent/JP2009531410A/en
Priority to EP07734153A priority patent/EP2004210A2/en
Publication of WO2007116278A2 publication Critical patent/WO2007116278A2/en
Publication of WO2007116278A3 publication Critical patent/WO2007116278A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

An angiostatin peptide fragment having antichemotactic, antiangiogenic and antitumor activities, pharmaceutical compositions containing it and their uses for the treatment of inflammatory, connective degenerative, vascular and neoplastic conditions.
PCT/IB2007/000831 2006-03-31 2007-03-30 Antiangiogenic peptide and therapeutic uses thereof WO2007116278A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009502246A JP2009531410A (en) 2006-03-31 2007-03-30 Anti-angiogenic peptides and their use for therapy
EP07734153A EP2004210A2 (en) 2006-03-31 2007-03-30 Antiangiogenic peptide and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2006A000625 2006-03-31
IT000625A ITMI20060625A1 (en) 2006-03-31 2006-03-31 ANTIANGIOGENIC PEPTIDE AND ITS THERAPEUTIC USES

Publications (2)

Publication Number Publication Date
WO2007116278A2 WO2007116278A2 (en) 2007-10-18
WO2007116278A3 true WO2007116278A3 (en) 2007-12-21

Family

ID=38462067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/000831 WO2007116278A2 (en) 2006-03-31 2007-03-30 Antiangiogenic peptide and therapeutic uses thereof

Country Status (4)

Country Link
EP (1) EP2004210A2 (en)
JP (1) JP2009531410A (en)
IT (1) ITMI20060625A1 (en)
WO (1) WO2007116278A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643318A1 (en) 2013-06-07 2020-04-29 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018030A2 (en) * 1999-09-03 2001-03-15 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2006040157A1 (en) * 2004-10-15 2006-04-20 Istituto Nazionale Per La Ricerca Sul Cancro Anti-angiogenic peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018030A2 (en) * 1999-09-03 2001-03-15 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2006040157A1 (en) * 2004-10-15 2006-04-20 Istituto Nazionale Per La Ricerca Sul Cancro Anti-angiogenic peptide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SULOCHANA K N ET AL: "Developing antiangiogenic peptide drugs for angiogenesis-related diseases.", CURRENT PHARMACEUTICAL DESIGN 2007, vol. 13, no. 20, 2007, pages 2074 - 2086, XP009089402, ISSN: 1873-4286 *
WAHL MIRIAM L ET AL: "Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated.", JOURNAL OF CELLULAR BIOCHEMISTRY 1 OCT 2005, vol. 96, no. 2, 1 October 2005 (2005-10-01), pages 242 - 261, XP009089377, ISSN: 0730-2312 *

Also Published As

Publication number Publication date
EP2004210A2 (en) 2008-12-24
ITMI20060625A1 (en) 2007-10-01
WO2007116278A2 (en) 2007-10-18
JP2009531410A (en) 2009-09-03

Similar Documents

Publication Publication Date Title
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
GB2430367B (en) Ion binding polymers and uses thereof
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2008120098A3 (en) Peptide prodrugs
WO2008121767A3 (en) Stitched polypeptides
UA97502C2 (en) Crystalline solid basis of rasagilin
MX2009006536A (en) Organic compounds and their uses.
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2008034124A3 (en) Targeted polymeric prodrugs containing multifunctional linkers
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2008002591A3 (en) Methods for treating atherosclerosis
WO2008008923A3 (en) Compositions and methods for targeting cancer-specific transcription complexes
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2006113568A3 (en) Controlled delivery dosage form of tramadol and gabapentin
WO2007121124A3 (en) Hcv inhibitors comprising beta amino acids and their uses
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
WO2010037095A3 (en) Agents and methods for the treatment of cancer
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2010047823A3 (en) Detection and modulation of cytochrome c acetylation
WO2007101106A3 (en) Compositions and methods for modulating hemostasis using variant forms of activated factor v
WO2008081268A3 (en) Pharmaceutical compositions of entacapone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07734153

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009502246

Country of ref document: JP

Ref document number: 2007734153

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE